Journal: eLife
Article Title: Immunogenicity and safety of a live-attenuated SARS-CoV-2 vaccine candidate based on multiple attenuation mechanisms
doi: 10.7554/elife.97532
Figure Lengend Snippet: Figure 2. Immunogenicity of the vaccine candidate in hamsters. (A) Hamsters were inoculated with 1 × 103 or 1 × 104 plaque-forming unit (PFU) of BK2102 intranasally, and the serum was collected 4 weeks after inoculation. Spike-specific IgG in the sera of BK2102-inoculated hamsters and mock- treated hamsters was detected by ELISA. Symbols depict data of individual hamsters (n=10), and bars correspond to the median value. The limit of dilution is indicated in the x-axis. (B) Neutralizing antibodies in the sera were induced in BK2102-inoculated hamsters. Neutralizing antibodies in the
Article Snippet: Biotinylated anti- Syrian hamster IgG1 Ab (Southern Biotech, Cat# 1940- 08, 1/100 dilution), IgG2/3 subclass Ab (Southern Biotech, Cat# 1935- 08, 1/200,000 dilution), and IgA Ab (Brookwood Biomedical, Cat# 3003a, 1/100 dilution) were used and detected with HRPlabeled streptavidin (Abcam, Cat# ab7403, 1/10,000 dilution).
Techniques: Immunopeptidomics, Enzyme-linked Immunosorbent Assay